Genetic Analysis AS (XSAT:GEAN)

Market Cap	43.89M +34.7%
Revenue (ttm)	19.36M +2.4%
Net Income	-10.44M
EPS	-0.16
Shares Out	69.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,961
Average Volume	38,773
Open	0.5940
Previous Close	0.6300
Day's Range	0.5940 - 0.6400
52-Week Range	0.5560 - 2.6000
Beta	2.11
RSI	47.22
Earnings Date	May 29, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Colle...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 16
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: GEAN

Financial Performance

In 2025, Genetic Analysis AS's revenue was 21.17 million, an increase of 2.36% compared to the previous year's 20.68 million. Losses were -11.41 million, -22.72% less than in 2024.

Financial numbers in NOK